A Highly Selective, Cell-Permeable Fluorescent Probe for Imaging Histone Deacetylase 6 in Live Cells

Văn Thắng Nguyễn1,2, Tanja Koenen3, Jonas Bucevičius1

  • 1Chromatin Labeling and Imaging group, Department of NanoBiophotonics, Max Planck Institute for Multidisciplinary Sciences, Am Fassberg 11, Göttingen 37077, Germany.

Insights

Researchers developed a new chemical probe, 6SiR-C3-NextA, to visualize Histone Deacetylase 6 (HDAC6) in living cells. This tool aids in understanding HDAC6

Area of Science:

  • Biochemistry
  • Cell Biology
  • Chemical Biology

Background:

  • Histone Deacetylase 6 (HDAC6) is vital for cellular functions like cytoskeletal regulation and stress responses.
  • HDAC6 dysregulation is implicated in cancers and neurodegenerative diseases, highlighting its therapeutic potential.
  • Limited chemical tools for HDAC6 visualization hinder understanding of its dynamic roles in living systems.

Purpose of the Study:

  • To develop a novel chemical probe for visualizing HDAC6 in living cells.
  • To investigate the dynamic functions of HDAC6 using advanced imaging techniques.

Main Methods:

  • Development of the 6SiR-C3-NextA probe, based on the selective HDAC6 inhibitor Nexturastat A and a silicon-rhodamine fluorophore.
  • Biochemical and cellular assays to determine probe affinity, selectivity, and cytotoxicity.
  • Super-resolution microscopy to visualize endogenous HDAC6 localization and dynamics in various cell lines.

Main Results:

  • The 6SiR-C3-NextA probe exhibits high affinity (Kdapp = 21 ± 4 nM) and functional selectivity for HDAC6.
  • The probe is cell-permeable, shows low cytotoxicity, and is compatible with super-resolution imaging.
  • Successful visualization of endogenous HDAC6, its association with microtubules, and recruitment to stress granules in living cells.

Conclusions:

  • 6SiR-C3-NextA is a valuable chemical tool for studying HDAC6 dynamics in real-time.
  • The probe enables new insights into HDAC6's role in cellular processes and disease pathogenesis.
  • This development opens avenues for exploring HDAC6-targeted therapies.